These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21123101)

  • 1. Using targeted therapies alone for rheumatoid arthritis.
    Prati C; Wendling D
    Joint Bone Spine; 2011 Jan; 78(1):1-3. PubMed ID: 21123101
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical repercussions of introducing biological therapies: the well-controlled patient.
    Tornero-Molina J
    Reumatol Clin; 2015; 11(3):131-2. PubMed ID: 25769793
    [No Abstract]   [Full Text] [Related]  

  • 3. Failure to control progression of rheumatoid arthritis after a decade of biologic therapy.
    Scheinberg M; Filippi RZ; Hands R; Pitzalis C
    J Rheumatol; 2012 Oct; 39(10):2049-50. PubMed ID: 23028032
    [No Abstract]   [Full Text] [Related]  

  • 4. Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.
    Russell AS; Olszynski WP; Davison KS; Koehn C; Haraoui B
    Clin Rheumatol; 2010 Mar; 29(3):233-9. PubMed ID: 20039183
    [No Abstract]   [Full Text] [Related]  

  • 5. The risk of infections with biologic therapies for rheumatoid arthritis.
    Furst DE
    Semin Arthritis Rheum; 2010 Apr; 39(5):327-46. PubMed ID: 19117595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Proposal for biologic drugs therapy in rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S
    Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale of using different biological therapies in rheumatoid arthritis.
    Geyer M; Müller-Ladner U
    Arthritis Res Ther; 2010; 12(4):214. PubMed ID: 20735862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotherapy and rheumatoid arthritis: a medico-economic evaluation from 2008 French Hospital Database.
    Maravic M; Baudens G; Sanchez JP; Flipo RM; Toubiana L; Landais P
    Joint Bone Spine; 2012 Jan; 79(1):96-7. PubMed ID: 21803635
    [No Abstract]   [Full Text] [Related]  

  • 9. Recommendations for the therapeutics of methotrexate in rheumatoid arthritis.
    Murphy G; Coughlan R; Devlin J; FitzGerald O; McCarthy G
    Ir Med J; 2009 Jun; 102(6):170-2. PubMed ID: 19722351
    [No Abstract]   [Full Text] [Related]  

  • 10. Ultrasound versus clinical joint level assessment to predict structural damage in rheumatoid arthritis patients receiving biological therapy: a prospective study.
    Minowa K; Ogasawara M; Matsuki-Muramoto Y; Kawamoto T; Yamaji K; Tamura N
    Clin Exp Rheumatol; 2020; 38(4):801. PubMed ID: 32141426
    [No Abstract]   [Full Text] [Related]  

  • 11. Guidelines for the drug treatment of rheumatoid arthritis.
    Mota LM; Cruz BA; Brenol CV; Pereira IA; Rezende-Fronza LS; Bertolo MB; Freitas MV; Silva NA; Louzada-Junior P; Giorgi RD; Lima RA; Bernardo WM; Pinheiro Gda R;
    Rev Bras Reumatol; 2013 Apr; 53(2):158-83. PubMed ID: 23856794
    [No Abstract]   [Full Text] [Related]  

  • 12. Back to the future: the managed care approach to rheumatoid arthritis.
    Sidorov J
    Manag Care Interface; 2007 Jul; 20(7):28-30. PubMed ID: 17849731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic therapy for rheumatoid arthritis in developing countries--a place for non-TNF inhibitors as first-line treatment?
    Tikly M; Hodkinson B; Dheda K
    Rheumatology (Oxford); 2015 Feb; 54(2):208-9. PubMed ID: 24692577
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted therapies in rheumatoid arthritis: the need for action.
    Emery P; Panayi G; Sturrock R; Williams B
    Rheumatology (Oxford); 1999 Oct; 38(10):911-2. PubMed ID: 10534539
    [No Abstract]   [Full Text] [Related]  

  • 15. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
    Deighton C; Hyrich K; Ding T; Ledingham J; Lunt M; Luqmani R; Kiely P; Bukhari M; Abernethy R; Ostor A; Bosworth A; Gadsby K; McKenna F; Finney D; Dixey J;
    Rheumatology (Oxford); 2010 Jun; 49(6):1197-9. PubMed ID: 20308121
    [No Abstract]   [Full Text] [Related]  

  • 16. Revolutionary change in rheumatoid arthritis management with biological therapy.
    Takeuchi T
    Keio J Med; 2011; 60(3):75-81. PubMed ID: 21979826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COMET's path, and the new biologicals in rheumatoid arthritis.
    Kremer JM
    Lancet; 2008 Aug; 372(9636):347-8. PubMed ID: 18635257
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.
    Combe B; van Vollenhoven R
    Ann Rheum Dis; 2013 Sep; 72(9):1433-5. PubMed ID: 23625979
    [No Abstract]   [Full Text] [Related]  

  • 19. Treating to target in rheumatoid arthritis: biologic therapies.
    Firth J; Critchley S
    Br J Nurs; 2011 Nov 10-23; 20(20):1284, 1287-8, 1290-1. PubMed ID: 22068002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More positive outcomes for patients with arthritis.
    El Miedany Y; Palmer D
    Br J Nurs; 2013 Mar 28-Apr 10; 22(6):356. PubMed ID: 23905220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.